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Introduction
Myeloid leukemia is the result of uncontrolled clonal pro­
liferation  in  the  erythroid,  monocytic  and  granulocyte 
lineages and their precursors, originating from hemato­
poietic stem cells of the bone marrow (Figure 1). It can be 
roughly divided into acute and chronic disease, reflecting 
disease development and survival if untreated (Table 1), 
but the World Health Organization classifica  tion of the 
various  subsets  of  acute  and  chronic  leukemia  is 
increasingly dependent on molecular diagnostics because 
of the wider use of targeted therapy.
Myeloid  leukemia  frequently  involves  mutations  of 
signal transduction pathways, including mutations of the 
tyrosine­specific protein kinase Janus kinase 2 (JAK2) in 
erythroid  neoplasia,  the  pathognomonic  BCR-ABL 
(break  point  cluster  region­Abelson)  kinase  gene  trans­
loca  tion in chronic myeloid leukemia (CML), and FMS­
like  tyrosine  kinase  3  (FLT3)  gene  mutation  in  acute 
myeloid leukemia (AML) [1,2]. All of these mutations are 
proposed to activate signal transduction pathways, which 
either belong to the wild­type kinase counterpart or, in 
the  case  of  FLT3  mutation  of  the  juxta  membranous 
region, activate parallel signal transduction pathways that 
are not activated by ligand­stimulated wild­type FLT3. In 
AML,  the  FLT3  gene  is  mutated  in  more  than  25%  of 
patients,  but  inhibitors  of  FLT3  have  so  far  not  been 
proven to enhance overall survival.
The fact that the BCR-ABL gene chimera in CML is 
drug­able has revolutionized the treatment of this serious 
disease. Overall 5­year survival in the pre­tyrosine kinase 
inhibitor  (TKI)  era  was  approximately  50%,  compared 
with over 80% survival at 6 years in patients treated with 
imatinib [3]. Patients usually experience tolerable side­
effects  that  predominantly  reflect  the  off­targets  of 
imatinib,  for  example,  platelet­derived  growth  factor 
recep  tor inhibition leading to edema. A chemical proteo­
mic approach [4] has identified new protein targets for 
imatinib, and a similar strategy has recently been used for 
target validation of the broader TKI dasatinib [5]. JAK2 is 
currently  being  explored  as  a  therapeutic  target  with 
novel TKIs in phase II and III trials of polycythemia vera, 
an erythroid neoplasia [6].
The  common  genetic  and  mutational  features  of 
myeloid leukemic cells usually imply a profound effect on 
protein networks of the leukemic cell. Proteomics include 
a collection of techniques that ideally allow the analysis 
of all proteins in a defined protein network within a cell, 
in a certain subcellular compartment or a functional part 
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© 2010 BioMed Central LtdFigure 1. Myeloid leukemia and normal hematopoiesis. Acute myeloid leukemia (AML; red box) is a hematological disease characterized by 
a block in differentiation and promotion of proliferation or survival. Recurrent genetic abnormalities include t(8;21)(q22;q22), inv(16)(p13.1q22), 
t(16;16)(p13.1q22), t(15;17)(q22;q21), and t(9;11)(p22;q23). Chronic myeloid leukemia (CML; green box) is characterized as a stem cell disease 
with hyperplastic myeloid cells, including both immature and mature myeloid cells. The disease is defined by occurrence of the BCR-ABL fusion 
gene in the Philadelphia chromosome. Juvenile myelomonocytic leukemia (JCMML) and chronic myelomonocytic leukemia (CMML) (blue box) 
are hematological diseases with features of a myeloproliferative neoplasm and a myelodysplastic syndrome. Characteristics are peripheral blood 
monocytosis >1 × 109/l, no Philadelphia chromosome or BCR-ABL fusion gene, no rearrangement of platelet-derived growth factor receptor alpha 
polypeptide, or platelet-derived growth factor receptor beta polypeptide, and >20% blasts in the blood and bone marrow. The figure was kindly 
provided by Dr Line Wergeland, University of Bergen.
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Page 2 of 10of a cell, and in a specific type of cell, organ, tissue, or 
extra  cellular fluid. Therefore, proteomics should be the 
ideal  tool  for  the  prediction  of  response  to  targeted 
therapy, as well as for monitoring targeted therapy.
In this review we will focus on proteomic analysis of 
the leukemic cells in CML, juvenile chronic myelomono­
cytic leukemia (JCMML), adult chronic myelomonocytic 
leukemia  (CMML),  and  AML  (Figure  1),  and  illustrate 
how proteomics may create new diagnostics and mole­
cular  classifications  for  the  disease.  Current  proteomic 
studies  are  clearly  technology  driven  and  research  is 
influenced by the recent technological advances of the 
field.  We  will  discuss  selected  methodologies  that  are 
particularly  powerful  for  biomarker  screening  or  the 
analysis of limited clinical material. The methodological 
pipeline to identify promising biomarkers for disease and 
therapy  response  will  be  discussed,  as  well  as  how 
recognized and verified biomarkers may be transferred 
into  an  assay  format  that  fits  the  routine  laboratory 
(Figure 2).
Leukemia derived from the myeloid lineage of 
hematopoietic stem cells
Myeloid  leukemia  includes  some  of  the  most  well 
understood malignancies in humans, but also rare and 
less definable diseases. CML is characterized by a massive 
clonal expansion of mature granulocytes and precursors. 
The  disease  progresses  through  three  distinct  phases  ­ 
chronic phase, accelerated phase, and blast crisis ­ during 
which the leukemic clone progressively loses its ability to 
differentiate. CML has been considered to be a unique 
model to understand the molecular mechanisms under­
lying  the  onset  and  progression  of  a  leukemic  process 
since it was the first recognized form of cancer to have a 
strong association with a recurrent chromosomal abnor­
mality.  This  abnormality  is  a  reciprocal  translocation 
between the long arms of chromosomes 9 and 22 (t(9;22)), 
which generates the so­called Philadelphia chromo  some 
[7] (Table 1). This abnormality was later discovered to be 
a  specific  molecular  defect,  a  hybrid  BCR-ABL  gene, 
coding for a tyrosine­specific protein kinase. The intro­
duc  tion into clinical practice of the first­generation TKIs ­ 
for example, imatinib ­ represented a major breakthrough 
in the era of molecular targeted therapy [8,9].
In contrast to the relative homogeneity of CML, AML 
is a clinically and genetically heterogeneous disease that 
results  from  the  transformation  and  proliferation  of 
immature  myeloid  cells  that  suppress  normal  bone 
marrow  function  [10­12].  Untreated  patients  have  a 
median  survival  of  only  2  to  4  months,  and  intensive 
chemo  therapy, eventually in combination with allogeneic 
hematopoietic  stem  cell  transplantation,  is  the  only 
possibility  for  cure  [10].  The  first  subclassification  in 
AML was based on leukemic cell morphology and histo­
chemistry  [10],  and  was  named  the  French­American­
British system [13], but this classification has proved to 
be of limited predictive value in determining prognosis 
and guidance for therapy. Acute promyelocyte leukemia 
(APL) is an important exception, since this morphological 
AML variant comprises a balanced reciprocal transloca­
tion  between  chromosomes  15  and  17  (t(15;17))  [14] 
(Table  1).  Patients  with  APL  have  a  particularly  good 
prog  nosis  after  the  introduction  of  vitamin  A  in  the 
treatment  [14]  since  the  chimeric  retinoid  receptor  in 
t(15;17) makes the leukemic cells sensitive for undergoing 
maturation  and  early  cell  death  when  treated  with 
Table 1. The main morphological, clinical, cytogenetic and molecular genetic characteristics, and treatment options, in 
the major myeloid malignancies
Characteristics/ 
treatment options  CML  CMML  APL  AML
Morphological   Proliferation of mature  Proliferation of monocytes,   Accumulation of  Accumulation of immature 
characteristics  granulocytes and precursors  also dysplasia in other cell   promyelocytes  myeloid cells 
    lineages   
Clinical characteristics  Mild symptoms (malaise, low   Bone marrow failure; often  Often severe bone marrow  Often severe bone marrow failure 
  fever), often asymptomatic;   general symptoms: weight  failure (anemia, infection,   (anemia, infection, bleeding); 
  slow progression of disease  loss, night sweats  bleeding) often coagulopathy;  aggressive disease 
      aggressive disease 
Cytogenetic   Reciprocal translocation  Several described; could also  Balances reciprocal  Several described; could also be 
characteristics  between chromosomes 9   be normal (60% to 70%)  translocation between  normal (45%) 
  and 22 t(9;22)    chromosomes 15 and    
      17 t(15;17) 
Molecular genetic   Probably important in  Several described; RAS family  None recognized  Several discovered, 
characteristics  disease development and   (N-RAS/K-RAS) seems of    important in risk stratification 
  resistance to TKIs  special interest   
Main treatment options  First- and second-generation   Chemotherapeutics,   ATRA, arsenic trioxide,   Chemotherapeutics, allo-SCT 
  TKIs, allo-SCT  5-azacitidine, allo-SCT  chemotherapeutics, allo-SCT 
allo-SCT, allogenic stem cell transplantation; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CML, chronic myeloid 
leukemia; CMML, chronic myelomonocytic leukemia; TKI, tyrosine kinase inhibitor.
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Page 3 of 10Figure 2. Workflow for identification, verification and application of biomarkers in clinical diagnostics. Stable isotope labeling with amino 
acids in cell culture (SILAC), difference gel electrophoresis (DIGE) and isobaric tags for relative and absolute quantification (iTRAQ) are all powerful 
tools for finding differences in protein production in separate samples. A marker is added to the samples during either the experiment or the 
preparation for analysis; the samples are then analyzed together and in the resulting data can be told apart on account of the different markers. 
The aim is to find proteins that significantly differ in expression between the samples. For further validation, reverse-phase protein array (RPPA), and 
especially multiple reaction monitoring (MRM), are highly sensitive methods that can detect subtle differences in production of proteins identified 
as potential biomarkers. RPPA is an antibody-based assay that detects and quantifies protein production. MRM allows detection and absolute 
quantification of protein based on internal standard peptides. A suitable peptide, fulfilling the criteria to enable optimal analysis, is chosen from 
within the target protein and then produced with a heavy isotope amino acid incorporated. This synthetic peptide is added in known amounts to 
the sample. In the triple quadruple instrument (QQQ), the peptides of interest are selected (Q1), fragmented (Q2) and the resulting target peptide 
ions selected (Q3) for detection. As the amount of standard peptide added to the sample is known, peak comparison allows calculation of the 
amount of the target protein present in the sample. To apply identified and validated biomarkers in clinical diagnostics, the analytical method 
must be highly reproducible. Flow cytometry is a well-established method of analyzing hematological samples. With the application of mass 
spectrometry detection after flow cytometry selection (ICPTOF-MS), problems with multiplexing are overcome, and this method enables detection 
of up to 20 biomarker proteins. The nanofluidic proteomic assay (NIA) method allows quantitative detection of protein production in very limited 
material. The proteins are separated according to isoelectric point inside capillary glass tubes before immobilization and antibody detection.
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Page 4 of 10vitamin  A.  However,  AML  represents  a  heterogeneous 
condi  tion,  reflecting  the  fact  that  leukemic  transfor­
mation  can  occur  at  different  steps  along  the  differ­
entiation pathway. Large clinical studies have proposed 
cytogenetic risk systems categorizing patients with AML 
into three groups: favorable, intermediate, and adverse. 
Nevertheless, approximately 50% of AML patients lack 
cytogenetic aberrations; because of this, gene expression 
profiles,  DNA  methylation  patterns,  micro  RNA 
expression,  protein  production,  chemokine  production, 
and  signal  transduction  responses  have  been  used  in 
subclassification  [11,12,15,16].  Consequently,  the 
treatment  principle  of  ‘one  size  fits  all’  has  been 
challenged  considerably  over  the  past  decades,  even  if 
mole  cular classification has been translated into highly 
individualized chemotherapy in clinical trials [11].
An interesting third group of myeloid leukemia, which 
is  difficult  to  fit  into  either  the  chronic  or  acute 
categories, is CMML and its pediatric variant JCMML 
[17]. By definition, CMML excludes the presence of the 
Philadelphia chromosome, but as many as 30% to 40% of 
cases show different cytogenetic abnormalities. In most 
cases of CMML, the critical genetic lesions remain un­
identi  fied.  However,  the  proto­oncogene  family  RAS 
seems to be of special interest. N­RAS and K­RAS are 
highly mutated in CMML, and recent research indicates 
that RAS is particularly important in the development 
and progression of the disease [18,19].
Proteomic technologies for analysis of leukemia
The identification of proteins in cancer is predominantly 
performed  by  mass  spectrometry  (MS)  analysis  of 
fractionated proteins, or indirectly through probing with 
well­characterized antibodies. The strength of antibody­
based techniques lies in their signal amplification steps, 
which allow the detection of protein concentrations in 
the  femtomolar  range.  The  combination  of  antibodies 
and isoelectric protein focusing in a capillary tube format 
[20,21]  allows  the  detection  of  specified  proteins  and 
their  modifications  with  sensitivity  down  to  25  cells, 
depending on protein abundance. Certain MS methods, 
such as multiple reaction monitoring (MRM), are able to 
detect and quantify single proteins in the attomolar range 
[22,23], with a dynamic range extending over three orders 
of magnitude [24,25]. However, the fact that leukocytes 
include  multiple  cellular  subsets  requires  a  different 
technique able to distinguish between various cell types. 
Flow cytometric determination of blood cells using anti­
bodies  against  extra­  and  intracellular  targets  provides 
the  user  with  information  about  such  cellular  subsets, 
and  represents  a  fundamental  test  in  leukemia  diag­
nostics. How can we extend the repertoire of antibodies 
recognizing  relevant  proteins  in  leukemia  diagnostics? 
MS techniques such as stable isotope labeling with amino 
acids in cell culture (SILAC) can be used to identify new 
protein markers that can be developed for platforms such 
as flow cytometry.
Stable isotope labeling with amino acids in cell culture
SILAC  is  a  technique  based  on  MS  that  has  been 
developed  to  detect  quantitative  differences  in  protein 
levels  between  two  or  more  samples  [26]  (Figure  2). 
Different  cell  populations  are  grown  in  medium 
containing amino acids labeled with stable light or heavy 
isotopes.  After  a  certain  number  of  doublings,  the 
isotope­labeled  amino  acids  are  metabolically  incor­
porated into every protein of the cell. Equal amounts of 
protein  from  the  two  different  cell  populations  are 
combined, followed by standard procedures for sample 
preparation for MS analysis. The metabolic incorporation 
of the isotope­labeled amino acids leads to a mass shift of 
corresponding  peptides,  with  the  ratio  of  the  peak 
intensities reflecting the relative protein amount.
Until recently, the method was limited to the quanti­
fication  of  proteins  from  cultured  cells.  However,  the 
development of a SILAC mouse has expanded its utiliza­
tion  to  include  differential  studies  of  tissues  and 
biological fluids from animal models [27]. SILAC applica­
tions  include  studies  of  cellular  signaling,  post­trans­
lational  modifications  such  as  phosphorylation,  and 
protein­protein interactions, as well as protein expression 
profiling in normal versus diseased cells, and identifica­
tion of disease biomarkers and pharmacological targets. 
The method is frequently applied in mechanistic studies 
of drug­induced alterations of cellular signaling in differ­
ent diseases, including myeloid leukemias; for example, 
Xiong and Wang [28] used SILAC to examine the mecha­
nisms underlying the cytotoxicity and therapeutic activity 
of arsenic trioxide, an ancient and effective second­line 
drug for therapy of acute promyelocytic leukemia. Others 
have  applied  a  combination  of  SILAC  and  phospho­
proteomics: Pan et al. [29] studied the effects of different 
kinase  inhibitors  on  entire  phosphoprotein  networks, 
while  Liang  et  al.  [30]  quantified  imatinib­induced 
changes in the phosphorylation of BCR­ABL kinase and 
its substrates in human CML cells. SILAC has also been 
used  to  study  the  molecular  pathogenesis  of  myeloid 
leukemias, including studies of protein kinase regulation 
in myeloid leukemia cells compared with other cell types 
[31], and signaling induced by modulation of the FLT3 
receptor tyrosine kinase in AML cells [32]. Some of the 
future  applications  of  SILAC  that  hold  great  promise 
include the identification of biomarkers and pharmaco­
logical  targets  in  myeloid/lymphoid  or  mixed  lineage 
leukemia comprising t(4;11) translocations compared to 
other  types  of  leukemia  [33].  In  summary,  SILAC  is  a 
sensitive  method  for  the  study  of  novel  signal  trans­
duction pathways and pharmacological targets, and will 
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that can be brought into clinical use.
Two-dimensional difference gel electrophoresis
Two­dimensional electrophoresis is an effective method­
ology to separate proteins based on charge and size, and 
this  protein  separation  technique  combined  with  MS 
protein  identification  has  already  led  to  the  successful 
identification  of  experimental  therapy  targets  in  AML 
[34,35].  However,  limitations  in  reproducibility  and 
quanti  fication  have  led  to  the  development  of  the 
powerful two­dimensional differential gel electrophoresis 
(2D­DIGE)  [36,37].  Largely  correcting  for  technical 
variations, 2D­DIGE multiplexes two fluorescent­labeled 
protein  samples  with  an  internal  standard  [36].  The 
method improves the accuracy of protein quantification 
and  provides  highly  reproducible  results.  It  has  been 
widely used in the discovery of disease biomarkers, treat­
ment response and verification of disease classifica  tion. 
In myeloid leukemia, the accumulation of ubiquitinated 
proteins  in  the  cytosol  identified  in  the  APL  cell  line 
HL­60 treated with methotrexate was found to be caused 
by the apoptosis­associated downregulation of structural 
and  regulatory  proteasome  subunits  [38].  Shen  and 
colleagues [39] used 2D­DIGE to discover the involve­
ment of CRK­like protein (CRKL) in multidrug resistance 
of  the  CML  cell  line  K562/ADM,  thereby  supporting 
previous findings that suggested that the protein is impli­
cated in the pathogenesis of CML. Even though 2D­DIGE 
has clear limitations with respect to the representation of 
proteins  analyzed,  it  allows  the  researcher  to  narrow 
down  the  number  of  potential  protein  candidates  for 
identification  and  mapping  of  protein  modification, 
thereby  resulting  in  a  less  complex  sample  set  to  be 
further analyzed by MS to identify proteins with func­
tional impact on disease.
Isotope-coded affinity tags
Introduced by Gygi and co­workers in 1999 [40], isotope­
coded affinity tags (ICAT) was one of the first develop­
ments in quantitative proteomics. The reagents used are 
biotinylated derivates of iodoacetamide that react with 
the  cysteine  side  chains  of  reduced  and  denatured 
proteins.  Heavy  and  light  versions  of  the  reagents  are 
used to label the two different samples before they are 
combined and digested. Streptavidin affinity chromato­
graphy  excludes  peptides  that  do  not  contain  cysteine 
residues with biotin, and reduces the complexity of the 
sample.  Before  the  development  of  cleavable  ICAT 
[41,42], the presence of biotin complicated the analysis 
due to the additional weight of the biomarker. However, 
cleavable  ICAT  allows  the  cleavage  of  biotin  from  the 
peptide before the samples are analyzed by MS. The ratio 
between the heavy and light peptides is used to calculate 
the  relative  abundance  of  the  peptides  before  they  are 
identified by tandem MS (MS/MS). This method has high 
specificity  and  sensitivity,  and  can  be  applied  to  many 
different kinds of samples. The obvious disadvantage with 
ICAT  is  its  dependence  on  cysteine  residues,  as  this 
excludes proteins without this amino acid. Thus far, ICAT 
has been used to map basic protein interactions in myeloid 
cell lines [43] and mechanisms of differentiation [44].
Isobaric tags for relative and absolute quantification
Isobaric  tags  for  relative  and  absolute  quantification 
(iTRAQ)  allow  the  analysis  of  up  to  eight  separate 
samples  simultaneously  [45];  this  is  a  higher  level  of 
multiplexing  than  that  of  any  of  the  other  labeling 
methods  to  date.  After  digestion,  the  peptides  in  the 
samples are labeled with an isobaric tag on the primary 
amines (Figure 2). The samples are then combined before 
MS/MS analysis. The isobaric tags consist of a charged 
reporter group and a neutral balance group, which are 
combined so the different tags have identical molecular 
mass. In MS analysis, the combined samples appear as a 
single peak, with the different reporters becoming visible 
after  MS/MS.  During  fragmentation,  the  two  reporter 
groups split, releasing the neutral reporter. This makes 
the differently charged tags visible and the intensity of 
these ion peaks are a measurement of the relative abun­
dance of the peptide in the different samples. Griffiths 
and  colleagues  [46]  used  iTRAQ  to  explore  imatinib­
induced  effects  on  the  proteome  in  CML  CD34+  cells 
from patients presenting with chronic phase CML. They 
found  Asp­Glu­Ala­Asp  (DEAD)­box  protein  3,  heat 
shock protein 105 kDa, and peroxiredoxin­3 to be poten­
tial  markers  for  response  to  imatinib  treatment  [46]. 
Furthermore,  AML  cells  that  produce  wild­type  FLT3, 
internal  tandem  duplication  FLT3,  or  D835Y  point­
mutated FLT3 have been examined by iTRAQ to identify 
and  quantify  phosphotyrosines.  The  analysis  showed 
differences  in  protein  phosphorylation  of  JAK2,  signal 
trans  ducer and activator of transcription protein (STAT)5a, 
and  SH2­containing  protein  phosphate  (SHP1),  and  it 
was concluded that the mutations FLT­ITD and FLT3­
D835Y cause divergent signal responses in AML [47].
Reverse-phase protein arrays
Reverse­phase  protein  array  (RPPA)  is  a  rapid,  high­
throughput  technology  for  the  analysis  of  patient 
samples. Originally applied to the investigation of micro­
dissected tissue from prostate, colon, and head and neck 
cancer, it is also highly applicable to hematopoietic cells 
[48­50]. In short, cells are lysed and protein samples are 
spotted  onto  nitrocellulose­coated  glass  slides  with  an 
automated printer. Slides are blocked, blotted, and incu­
bated with antibodies before measuring signal intensity 
by  scanning  and  quantification  of  results  (Figure  2). 
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with  western  blotting  [51].  Tibes  and  colleagues  [51] 
validated the method for hematological cells, proving it 
to be highly reproducible, even in samples as scarce as 
the proteomic equivalent to three cells. Kornblau and co­
workers [52] used RPPA to propose that high levels of 
phosphorylation  of  the  tumor  suppressor  forkhead 
transcription factor 3A is an unfavorable, though thera­
peutically targetable, prognostic factor in AML. Pigazzi 
and  colleagues  [53]  observed  that  the  microRNA 
miR­34b  mediated  downregulation  of  several  target 
genes (for example, those encoding cyclins A1, B and D1) 
of cAMP response element­binding (CREB) in myeloid 
cell lines and bone marrow samples from pediatric AML 
patients, and this could possibly explain some of the cell 
cycle abnormalities found in myeloid cell lines. RPPA has 
also largely confirmed the prognostic value of Bax/Bcl­2 
protein production ratio and Mcl­1 production [54], as 
previously reported by flow cytometric analysis [55,56]. 
These  studies  show  the  potential  for  RPPA  in  high­
through  put  analysis  screening  for  variation  in  protein 
production in large patient cohorts.
Multiple reaction monitoring
An emerging strategy for the analysis of potential protein 
markers is the absolute quantification (AQUA) strategy 
used in selective reaction monitoring; this is also known 
as  MRM  [25,57].  The  high  sensitivity  of  this  method 
enables quantitative detection of low­abundance proteins 
(concentrations  down  to  attomolar  levels)  in  complex 
mixtures,  with  dynamic  range  extending  over  three 
orders of magnitude [22­25]. The AQUA strategy is based 
on  specific  detection  of  target  proteins  enabled  by 
internal  standard  peptides,  chosen  within  the  target 
protein, and produced with a heavy isotope amino acid 
incorporated [58] (Figure 2). This selective detection of 
the peptides makes this method the most sensitive of all 
the MS methods. MRM has, to date, not been applied in 
studies  of  myeloid  leukemia,  but  as  it  becomes  more 
wide  spread it is natural to assume that it will take on a 
more  prominent  role  as  a  tool  for  validation  of  bio­
markers and clinical diagnostics.
Multiparameter flow cytometry, mass cytometry, and 
single-cell proteomics
Flow cytometry has been used for the analysis of myeloid 
malignancies  for  several  decades  and  its  applications 
include  classification,  diagnosis  and  prognosis,  therapy 
response prediction, and monitoring of therapy response. 
Methodological advances in the form of multiparameter 
flow cytometry and analysis of entire signaling networks 
have  brought  this  methodology  into  the  group  of 
techniques  available  for  large­scale  protein  studies.  In 
2004, the Nolan group demonstrated a novel approach 
for the analysis of signaling networks of cancer cells [59], 
in which they used multiparameter flow cytometry for 
detection  of  induced  phosphoprotein  responses  at  the 
single­cell level in AML cells. They were thereby able to 
correlate specific signaling profiles with genetic features 
and clinical outcome [59]. The same team employed the 
technique to identify a specific STAT5 signaling signature 
in myeloid malignancies, and this correlated with specific 
clinical  and  biologic  correlates  [60].  The  analysis  of 
signaling profiles at the single­cell level makes it possible 
to  identify  pathways  that  are  activated  in  therapy­
resistant cells, as well as potential biomarkers for patient 
diagnosis  and  prognosis.  A  major  advantage  of  multi­
parameter flow cytometry is the small amount of material 
needed, making it ideal for analysis of patient samples. 
However,  there  are  several  limitations  to  the  method­
ology, including few detection channels, spectral overlap 
between signals from fluorescent labels of the antibodies 
used,  and,  not  least,  antibody  specificity  and  epitope 
blocking  in  a  cluttered  cell.  Recently,  limitations  in 
multiplexing  have  been  overcome  by  the  utilization  of 
element tagging of antibodies, followed by analysis using 
a mass cytometer, combining the principles of flow cyto­
metry and MS [61]. Many available stable isotopes (up to 
100)  can  be  used  in  the  tags,  enabling  simultaneous 
detection of proteins and gene transcripts in individual 
cells in a quantitative manner using inductively coupled 
plasma  time­of­flight  mass  spectrometry  with  high 
resolu  tion,  sensitivity,  and  speed  of  analysis.  Simul­
taneous  detection  of  20  surface  antigens  in  single­cell 
analysis of human leukemia cell lines and samples from 
patients with AML [62] has demonstrated the advantages 
of  the  approach,  avoiding  problems  with  detection 
channels, sample matrix, and stability of the experiment 
set­up, in addition to the modest requirements of patient 
material. All in all, this is a promising approach for the 
development of a rapid, sensitive, automated method for 
concomitant detection of many biomarkers in individual 
cells.  Further  development  of  data  collection  and  pro­
cess  ing, including multiparameter clustering algorithms, 
may  provide  a  novel  methodology  for  investigation  of 
signaling pathways and disease detection.
Nanofluidic proteomic assay
The nanofluidic proteomic assay aims to overcome the 
limitations  in  the  detection  of  potential  biomarkers  in 
limited  material  [20,21].  This  method,  based  on  iso­
electric focusing of cell lysate in capillary glass tubes and 
detection using antibodies and chemiluminescence, can 
identify and quantify protein production in as little as 
25 cells (Figure 2). The isoelectric separation can separate 
proteins with different phosphorylation states, which can 
provide insights into the regulation of the protein. Fan 
and co­workers [20] used this method to detect as little 
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three orders of magnitude. In the K562 CML cell line, 
they detected changes in phosphorylation of STAT3 and 
STAT5, and changes in activation of caspase 3 and extra­
cellular signal­related kinase (ERK)2 after treatment with 
imatinib [20]. The obvious limitation of the method is the 
dependency on antibodies and the need for combination 
with flow­based cell sorting if cell type specificity is to be 
obtained; however, if these obstacles are overcome, this 
method can be a powerful tool in diagnostics and the 
monitoring of disease.
Prospects for protein-based diagnostics and 
monitoring of response to therapy
Lessons from recent achievements in CML research may 
illustrate the future of protein­based diagnostics. CML is 
the  single  malady  with  apparently  perfect  correlation 
between the pathognomonic gene aberration BCR-ABL 
and a therapeutic kinase inhibitor that effectively inhibits 
ABL tyrosine kinase activity. A protein­based immuno­
assay for detection of the gene product BCR­ABL is in 
development,  and  will  allow  diagnostics  of  ABL­BCR­
positive leukemia using cellular protein extracts or single 
cell flow cytometry [63]. Future diagnosis of CML could 
thereby  be  based  on  protein  diagnostics,  using  PCR­
based DNA diagnostics only as confirmatory analysis.
Proteomic  analysis  of  CML  cell  lines  treated  with 
imatinib has revealed the modulation of several phospho­
protein targets [30]. SILAC analysis of imatinib­treated 
CML cells has demonstrated a 90% reduction in phos­
phorylation of BCR­ABL kinase, SHIP2 and Dok­2, and 
other  modulated  proteins,  including  SHIP1,  SH2­
contain  ing  protein  and  Casitas  B­lineage  lymphoma 
proto­oncogene.  Imatinib­treated  CML  cells  show  an 
attenuated  activation  of  ERK1  and  ERK2,  mitogen­
activated  kinase­1,  STAT3  and  STAT5,  and  c­Jun  N­
terminal kinase [20]. Phospho­CRKL has been proposed 
as a marker for monitoring patients with CML treated 
with imatinib and nilotinib [64], and may be a pseudo­
marker  for  detecting  resistance  against  TKI  treatment. 
Direct and indirect detection of resistance in BCR­ABL­
positive CML is underscored by reports of significantly 
lower  levels  of  BCR­ABL,  CRKL  (Tyr207)  and  AKT 
(Ser473)  in  resistant  patients.  CML  may  be  the  first 
disease where we achieve fully protein­based diagnostics 
and therapy response monitoring.
Conclusions
Future  use  of  protein­based  diagnostics  in  cancer  may 
reflect clearer the epigenetics and genome alterations in 
leukemia, and represent a test more directly related to 
the  cellular  protein  targets  of  therapeutics.  It  is  still 
unclear which technology platform will be the dominat­
ing workhorse in clinical proteomics, but a technology 
that is ‘open’ in terms of target selection seems to hold 
the  strongest  appeal.  Maybe  the  lessons  from  modern 
vitamin and hormone analysis indicate a promising path 
[65,66], as a high number of molecules can be identified 
and quantified in minute clinical samples. In diagnostics 
of leukemia, validated MS analysis of peptides, with high 
flexibility and high sensitivity, may allow determination 
of classification and therapeutic targets [67]. Cell­type­
specific analysis is necessary for diagnostic information 
in leukemia and other hematological malignancies; this 
analytic quality is currently provided by flow cytometry 
only.  Detection  of  modified  proteins  in  intracellular 
signal transduction pathways may represent a novel diag­
nostic tool, as exemplified in JCMML, where phospho­
specific  flow  cytometry  may  replace  cumbersome  and 
time­consuming  growth  assays  [60].  Furthermore, 
protein analyses may play a role in future monitoring of 
therapy  response  evaluation,  but  carefully  designed 
clinical  trials  will  be  needed  to  determine  the  role  of 
proteomics in therapy guidance.
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